AstraZeneca announced Wednesday enrolment of the first patient in a late-stage development programme for its experimental rheumatoid arthritis drug fostamatinib. The programme, which is called OSKIRA and is made up of three studies, is designed to investigate fostamatinib as a treatment for patients with an inadequate response to disease modifying anti-rheumatic drugs, including methotrexate. AstraZeneca plans to submits regulatory filings for the drug, which was licensed from Rigel Pharmaceuticals, in 2013.
Reference Articles
AstraZeneca initiates Phase III clinical development of fostamatinib for the treatment of rheumatoid arthritis - (AstraZeneca)
Astra starts final-stage trials of arthritis drug - (Forexpros)
Astra launches late-stage rheumatoid arthritis pill trials (free preview) - (The Wall Street Journal)
**Published in "First Word"
Diario digital con noticias de actualidad relacionadas con el mundo de la salud. Novedades, encuestas, estudios, informes, entrevistas. Con un sencillo lenguaje dirigido a todo el mundo. Y algunos consejos turísticos para pasarlo bien
Traductor
Subscribe to:
Post Comments (Atom)
CONTACTO · Aviso Legal · Política de Privacidad · Política de Cookies
Copyright © Noticia de Salud
No comments:
Post a Comment